c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 142 produtos para "c-Met/HGFR".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Emibetuzumab
CAS:Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Pureza:95% - 96.5% (SDS-PAGE); 98.8% (SEC-HPLC)Cor e Forma:Transparent LiquidPeso molecular:143.74 kDaSU 5616
CAS:SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.Fórmula:C13H8ClNOSPureza:98.84%Cor e Forma:SolidPeso molecular:261.73Ref: TM-T72021
1mg34,00€1mL*10mM (DMSO)67,00€5mg71,00€10mg100,00€25mg166,00€50mg245,00€100mg354,00€200mg495,00€Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Fórmula:C27H23FN4O4SPureza:99.39%Cor e Forma:White SolidPeso molecular:518.56Ref: TM-T13108
1mg52,00€5mg101,00€1mL*10mM (DMSO)127,00€10mg149,00€25mg244,00€50mg359,00€100mg510,00€200mg695,00€c-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Fórmula:C17H14N8SPureza:98.77%Cor e Forma:SolidPeso molecular:362.41Bozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Fórmula:C20H15F3N8Pureza:99.16%Cor e Forma:SolidPeso molecular:424.38Ref: TM-T10585
1mg92,00€5mg205,00€1mL*10mM (DMSO)227,00€10mg334,00€25mg595,00€50mg858,00€100mg1.198,00€200mg1.611,00€JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Fórmula:C20H12F2N6Pureza:98.84% - 99.74%Cor e Forma:Yellow SolidPeso molecular:374.35Ref: TM-T15617
1mg59,00€5mg130,00€1mL*10mM (DMSO)144,00€10mg200,00€25mg401,00€50mg557,00€100mg737,00€CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Fórmula:C20H20FN7O2Pureza:99.29%Cor e Forma:SolidPeso molecular:409.42Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Cor e Forma:Transparent LiquidPeso molecular:145.2 kDaOnartuzumab
CAS:Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Pureza:97.3%Cor e Forma:Transparent LiquidPeso molecular:146.99 kDaPROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Fórmula:C51H50F2N6O13Cor e Forma:SolidPeso molecular:992.97c-Met-IN-18
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.Fórmula:C21H15FN4O2Pureza:98%Cor e Forma:SolidPeso molecular:374.37Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Fórmula:C29H49N4O10PPureza:98.01%Cor e Forma:SolidPeso molecular:644.69Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Fórmula:C34H29ClF2N6O5Pureza:98%Cor e Forma:SolidPeso molecular:675.08Caveolin-1 (82-101) amide (human, mouse, rat)
CAS:Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in variousFórmula:C124H170N28O29Pureza:98%Cor e Forma:SolidPeso molecular:2516.85Anti-MSPR/RON/CD136 Antibody (H5B14)
Anti-MSPR/RON/CD136 Antibody (H5B14) is a functional neutralizing antibody against RON, inhibiting tumor cell invasiveness and significantly delaying colorectal cancer progression by downregulating the MSP/RON signaling axis.1D228
1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration ofPureza:98%Cor e Forma:Odour Solidc-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Fórmula:C16H13N7OPeso molecular:319.11816C-Met inhibitor D9
CAS:C-Met inhibitor D9 is a c-Met kinase inhibitor.Fórmula:C17H15N3O2Pureza:97.45%Cor e Forma:SolidPeso molecular:293.32c-Met-IN-17
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]Fórmula:C21H15FN4O2Pureza:98%Cor e Forma:SolidPeso molecular:374.37c-Met-IN-19
c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,Fórmula:C34H37Cl2FN4O7SPureza:98%Cor e Forma:SolidPeso molecular:735.65c-Met ligand-Linker Conjugate 1
c-Met ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that consists of a c-Met ligand and a PROTAC linker, capable of recruiting E3 ligase. This compound is used in the synthesis of PROTACc-Met degrader-5.Cor e Forma:Odour SolidBMS-777607
CAS:BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Fórmula:C25H19ClF2N4O4Pureza:98.16% - 98.56%Cor e Forma:SolidPeso molecular:512.89Ref: TM-T2658
2mg59,00€5mg86,00€10mg135,00€25mg251,00€50mg388,00€100mg690,00€200mg1.034,00€500mg1.550,00€PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Fórmula:C51H54N10O7Cor e Forma:SolidPeso molecular:919.037PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Fórmula:C25H22N8O5SPureza:98%Cor e Forma:SolidPeso molecular:546.56Norleual
CAS:Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.Fórmula:C41H58N8O7Pureza:98%Cor e Forma:SolidPeso molecular:774.95LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Fórmula:C18H11F3N4OPureza:99.58%Cor e Forma:Yellow SolidPeso molecular:356.3PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Fórmula:C45H41FN10O5Cor e Forma:SolidPeso molecular:820.87Zurletrectinib
CAS:Zurletrectinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent.Fórmula:C19H19F2N7O2Cor e Forma:SolidPeso molecular:415.4CE-355621
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer.Cor e Forma:Odour LiquidNarnatumab
CAS:Narnatumab (IMC-RON8) is a humanized antibody that targets the macrophage-stimulating receptor 1 (RON). Narnatumab blocks the binding of RON to its ligand, macrophage-stimulating protein (MSP), and inhibits receptor activation, thereby suppressing tumor cell proliferation and migration. It is being investigated for the treatment of advanced malignant solid tumors.Pureza:>95%Cor e Forma:LiquidPeso molecular:145.8 kDaSYN1143
CAS:SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Fórmula:C31H29FN4O5Pureza:99.69%Cor e Forma:SolidPeso molecular:556.58PF-04217903 methanesulfonate
CAS:PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Fórmula:C20H20N8O4SPureza:98%Cor e Forma:SolidPeso molecular:468.49Norleual TFA
Norleual TFA, Ang IV analog, inhibits HGF/c-Met (IC50: 3 pM), blocks AT4, and has strong antiangiogenic effects.Fórmula:C43H59F3N8O9Cor e Forma:SolidPeso molecular:888.97Pamufetinib mesylate
CAS:Pamufetinib mesylate (TAS-115 mesylate) is a VEGFR antagonist and c-Met inhibitor used in the study of cancer and respiratory diseases.Fórmula:C28H27FN4O7S2Pureza:98.91%Cor e Forma:White SolidPeso molecular:614.67Ensartinib hydrochloride
CAS:Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFórmula:C26H29Cl4FN6O3Pureza:98.73%Cor e Forma:SolidPeso molecular:634.36Ref: TM-T22324
1mg54,00€5mg114,00€1mL*10mM (DMSO)158,00€10mg177,00€25mg356,00€50mg580,00€100mg888,00€NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Fórmula:C20H16N6Pureza:97.24% - >99.99%Cor e Forma:SolidPeso molecular:340.38XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.Fórmula:C29H25FN4O5Pureza:98.60%Cor e Forma:SolidPeso molecular:528.53Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Fórmula:C31H29FN4O5Pureza:99.95% - 99.98%Cor e Forma:SolidPeso molecular:556.58Ref: TM-TQ0021
1mgA consultar2mg47,00€5mg67,00€1mL*10mM (DMSO)73,00€10mg95,00€25mg170,00€50mg294,00€100mg502,00€Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Cor e Forma:SolidPeso molecular:510.46Afatinib Dimaleate
CAS:Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Fórmula:C32H33ClFN5O11Pureza:98.11% - 99.87%Cor e Forma:White SolidPeso molecular:718.08Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Cor e Forma:SolidPeso molecular:632.65Ref: TM-T3113
2mg37,00€5mg54,00€10mg74,00€1mL*10mM (DMSO)74,00€25mg126,00€50mg195,00€100mg335,00€500mg803,00€NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Fórmula:C31H23F2N5O3Pureza:98.48%Cor e Forma:SolidPeso molecular:551.54BMS-794833
CAS:BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Cor e Forma:SolidPeso molecular:468.84BMS-2
CAS:BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.Fórmula:C25H16F2N4O3Pureza:98.33%Cor e Forma:SolidPeso molecular:458.42Ref: TM-T8326
1mg67,00€2mg88,00€5mg148,00€1mL*10mM (DMSO)170,00€10mg230,00€25mg430,00€50mg622,00€100mg898,00€Merestinib dihydrochloride
CAS:Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.Fórmula:C30H24Cl2F2N6O3Cor e Forma:White SolidPeso molecular:625.45Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Fórmula:C23H19Cl2FN6OPureza:98.80%Cor e Forma:SolidPeso molecular:485.34Ref: TM-T4260
2mg34,00€5mg49,00€1mL*10mM (DMSO)58,00€10mg64,00€25mg84,00€50mg92,00€100mg126,00€500mg303,00€Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H21Cl2FN6O2Pureza:99.77%Cor e Forma:SolidPeso molecular:503.36Ref: TM-T8825
2mg34,00€5mg48,00€1mL*10mM (DMSO)50,00€10mg63,00€25mg84,00€50mg92,00€100mg126,00€500mg250,00€BMS817378
CAS:BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).Fórmula:C24H18ClF2N4O7PPureza:>99.99%Cor e Forma:White SolidPeso molecular:578.85Tivantinib
CAS:Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Fórmula:C23H19N3O2Pureza:98% - 99.41%Cor e Forma:Yellow SolidPeso molecular:369.42Hepln-13
CAS:Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Fórmula:C17H13BrN2Pureza:97.67%Cor e Forma:SolidPeso molecular:325.2Ref: TM-T25492
1mg35,00€2mg52,00€5mg80,00€1mL*10mM (DMSO)92,00€10mg119,00€25mg231,00€50mg344,00€100mg480,00€200mg663,00€
